US Patent

US9597281 — Pharmaceutical formulations useful in the treatment of insomnia

Method of Use · Assigned to Orexo AB · Expires 2027-04-06 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a formulation for transmucosal administration of a short-acting hypnotic drug, such as zolpidem, that provides a measurable plasma concentration within 10 minutes.

USPTO Abstract

There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-674 — zolpidem-tartrate
U-674 — zolpidem-tartrate

Patent Metadata

Patent number
US9597281
Jurisdiction
US
Classification
Method of Use
Expires
2027-04-06
Drug substance claim
No
Drug product claim
No
Assignee
Orexo AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.